Bacterial-Viral Interactions in Human Orodigestive and Female Genital Tract Cancers: A Summary of Epidemiologic and Laboratory Evidence

Infectious agents, including viruses, bacteria, fungi, and parasites, have been linked to pathogenesis of human cancers, whereas viruses and bacteria account for more than 99% of infection associated cancers. The human microbiome consists of not only bacteria, but also viruses and fungi. The microbiome co-residing in specific anatomic niches may modulate oncologic potentials of infectious agents in carcinogenesis. In this review, we focused on interactions between viruses and bacteria for cancers arising from the orodigestive tract and the female genital tract. We examined the interactions of these two different biological entities in the context of human carcinogenesis in the following three fashions: (1) direct interactions, (2) indirect interactions, and (3) no interaction between the two groups, but both acting on the same host carcinogenic pathways, yielding synergistic or additive effects in human cancers, e.g., head and neck cancer, liver cancer, colon cancer, gastric cancer, and cervical cancer. We discuss the progress in the current literature and summarize the mechanisms of host-viral-bacterial interactions in various human cancers. Our goal was to evaluate existing evidence and identify gaps in the knowledge for future directions in infection and cancer.

Bioinformatics Analysis of Long Non-coding RNA and Related Diseases: An Overview

Long non-coding RNAs (lncRNAs) are usually located in the nucleus and cytoplasm of cells. The transcripts of lncRNAs are >200 nucleotides in length and do not encode proteins. Compared with small RNAs, lncRNAs have longer sequences, more complex spatial structures, and more diverse and complex mechanisms involved in the regulation of gene expression. LncRNAs are widely involved in the biological processes of cells, and in the occurrence and development of many human diseases. Many studies have shown that lncRNAs can induce the occurrence of diseases, and some lncRNAs undergo specific changes in tumor cells. Research into the roles of lncRNAs has covered the diagnosis of, for example, cardiovascular, cerebrovascular, and central nervous system diseases. The bioinformatics of lncRNAs has gradually become a research hotspot and has led to the discovery of a large number of lncRNAs and associated biological functions, and lncRNA databases and recognition models have been developed. In this review, the research progress of lncRNAs is discussed, and lncRNA-related databases and the mechanisms and modes of action of lncRNAs are described. In addition, disease-related lncRNA methods and the relationships between lncRNAs and human lung adenocarcinoma, rectal cancer, colon cancer, heart disease, and diabetes are discussed. Finally, the significance and existing problems of lncRNA research are considered.

The Integrative Analysis of Thrombospondin Family Genes in Pan-Cancer Reveals that THBS2 Facilitates Gastrointestinal Cancer Metastasis

Recent cancer studies have found that the thrombospondin (THBS) family, including THBS1, THBS2, THBS3, THBS4, and THBS5, play vital roles in the development and progression of human cancers. However, their relationships with tumor stage, prognosis, and tumor immunity in pan-cancer have not been systematically reported. In the present study, we employed versatile public databases to assess the expression and mutations of different THBSs in pan-cancer and performed functional experiments to analyze the roles of THBS2 in gastrointestinal cancer metastasis. Our findings indicate that THBS genes are frequently mutated in various cancers and the dysregulation of THBS family members is associated with the progression of some cancers such as gastric cancer, colon cancer, and lung cancer. Further analyses indicate that THBS genes are associated with cancer hallmarks such as cell cycle and epithelial-mesenchymal transition (EMT). Importantly, thrombospondins, especially THBS1 and THBS2, are correlated with the immune cell infiltration level in gastrointestinal cancers. Our experiments further verified that THBS2 participates in tumor metastasis by enhancing EMT. Therefore, the overall analyses reveal that THBSs might offer us potential chances for tumor diagnosis and therapy.

Association between Coffee Consumption/Physical Exercise and Gastric, Hepatic, Colon, Breast, Uterine Cervix, Lung, Thyroid, Prostate, and Bladder Cancer

Although the effects of coffee consumption and physical exercise on the risk of cancer have been suggested, their interactions have not been investigated. The present cross-sectional study aimed to investigate the correlation of coffee consumption and physical exercise with cancer. Participants ≥40 years old in the Korean Genome and Epidemiology Study 2004–2016 were included (n = 162,220). Histories of gastric cancer, hepatic cancer, colon cancer, breast cancer, uterine cervix cancer, lung cancer, thyroid cancer, prostate cancer, and bladder cancer were analyzed according to the coffee consumption groups using logistic regression models. The odds among individuals in the >60 cups/month coffee group were lower for gastric cancer (adjusted odds ratio (aOR) = 0.80 (95% confidence intervals = 0.65–0.98)), hepatic cancer (0.32 (0.18–0.58)), colon cancer (0.53 (0.39–0.72)), breast cancer (0.56 (0.45–0.70)), and thyroid cancer (0.71 (0.59–0.85)) than for individuals in the no coffee group. Physical exercise of ≥150 min/week was correlated with higher odds for gastric cancer (1.18 (1.03–1.36)), colon cancer (1.52 (1.26–1.83)), breast cancer (1.53 (1.35–1.74)), thyroid cancer (1.42 (1.27–1.59)), and prostate cancer (1.61 (1.13–2.28)) compared to no exercise. Coffee consumption and physical exercise showed an interaction in thyroid cancer (p = 0.002). Coffee consumption was related to a decreased risk of gastric cancer, hepatic cancer, colon cancer, breast cancer, and thyroid cancer in the adult population. Physical exercise was positively correlated with gastric cancer, colon cancer, breast cancer, thyroid cancer, and prostate cancer.

Retrospective assessment of chemotherapy/biotherapy toxicity in a Hispanic/Latinx population versus published study population

Introduction Eskenazi Health in Indianapolis, Indiana, USA. services diverse communities in Central Indiana, including the Hispanic/Latinx community. It has been postulated that this population experiences toxicities at a higher rate and with a faster onset than the general population when treated with chemotherapy or biotherapy. The published clinical trials that have evaluated chemotherapy/biotherapy efficacy and toxicity have not adequately represented the Hispanic/Latinx population. This retrospective analysis aims to analyze the incidence and severity of adverse drug events in the Hispanic/Latinx population compared to the general study population. Methods A retrospective chart review included patients reported as Hispanic/Latinx in the electronic medical record who had breast cancer, colon cancer, acute myeloid leukemia, or multiple myeloma currently receiving chemotherapy/biotherapy and/or received chemotherapy/biotherapy during the study period. Seventy-three instances of patients receiving chemotherapy/biotherapy and 46 unique patients were included in the final analysis. Results Of the 73 instances, 29 (40%) had toxicity at baseline prior to chemotherapy/biotherapy received during the study period. Of those 29 baseline toxicities, 26 (90%) of them had new toxicity during the study period. Of the 73 instances, 62 (85%) experienced toxicities during the study period. Conclusion Ethnicity has a proven effect on medication efficacy and safety, but the specific impact of ethnicity on chemotherapy/biotherapy toxicity risk has not been well elucidated. This study found that a majority (85%) of Hispanic/Latinx patients treated with chemotherapy/biotherapy experienced toxicity of any grade, and the majority (90%) patients who had prior toxicity experienced another toxicity.

Research Progress on the Antitumor Effect of Polysaccharides from Fungus Used in Traditional Chinese Medicine

Cancer is a serious threat to human health. Fungal polysaccharide is a polar biological macromolecule with low toxicity. It has a wide range of biological activities, including immune regulation, antitumor activity, and antiviral activity. In recent years, the research results have shown that polysaccharides from fungus in traditional Chinese medicine have excellent antitumor effect in liver cancer, gastric cancer, breast cancer, colon cancer, esophageal cancer, and lung cancer. Therefore, the research and development of fungal polysaccharides are of great significance for the development of antitumor drugs in the future.

O impacto do uso da metformina no câncer colorretal: revisão integrativa

Objetivo: Avaliar o impacto do uso da metformina como droga antioncogênica no câncer colorretal. Métodos: Este trabalho constitui de uma revisão integrativa baseada na seleção criteriosa de artigos com a temática do impacto da metformina no câncer colorretal publicados nos últimos 10 anos nas bases de dados Pubmed e BVS com a combinação de descritores “metformin”, “colorectal cancer”, “colon cancer” e “rectal cancer”. Resultados: Foram encontrados, analisados e descritos 6 artigos (100%) sobre o referido tema, sendo que 4 (67%) foram estudos clínicos randomizados e 2 (33%) estudos clínicos controlados. Foi verificado que metformina pode impactar no câncer colorretal de duas formas distintas, porém não excludentes, atuando como uma quimioterapia, principalmente quimioterapia adjuvante à outras quimioterapias em pacientes com câncer de colorretal ou como quimioprevenção do câncer colorretal. Considerações finais: Os achados encontrados demonstram que apesar de poucas divergências a metformina pode ter um papel importante como droga antioncogênica atuando tanto na prevenção como no tratamento adjuvante do câncer colorretal, porém os estudos são iniciais e poucos, necessitando de maiores estudos clínicos para maior confiabilidade e utilização na prática clínica.

SYSCHRONOUS PRIMARY THYROID, LUNG AND COLON CANCERS: A CASE REPORT

Multiple primary neoplasms are relatively rare, but their incidence has increased because of aging and improvements in diagnostic imaging. There are many ways to classify, but nowadays, multiple primary cancers are again classified as synchronous and metachronous, the time is 6 months after the first primary injury detection, some authors get 12 months. Our clinical case is a 66-year-old man, prolonged exposure to risk factors for cancer. The patient was diagnosed with different types of primary cancer, colon cancer, thyroid cancer, lung cancer, and stomach cancer. The patient was treated according to the general clinical guidelines suitable for the disease type and the stage of the disease at the time of detection. Lesson learned is the importance of screening tests, attitudes, and comprehensive views of doctors for cancer patients, avoiding missing injuries, affecting the quality of treatment for patients.

Sendeng-4 Suppressed Melanoma Growth by Induction of Autophagy and Apoptosis

Sendeng-4 is a traditional Chinese medicine that has been successfully applied to anti-inflammatory diseases in clinical practice. Monomers within Sendeng-4 showed promising antitumor activity against lung cancer, colon cancer, and cutaneous cancer. However, potency of Sendeng-4 in melanoma has not been explored. This study aims to explore the potential application of Sendeng-4 in melanoma treatment. In the present study, we systemically investigate the possibility of Sendeng-4 for treatment of melanoma cancer in vitro by proliferation assay, colony formation, flow cell cytometry, RNA-seq, western blot, and fluorescence-based assay. Our data demonstrated that Sendeng-4 suppresses the proliferation and colony formation capacity of melanoma cells and induces cell cycle block at G2/M phase and eventually cell death. Mechanistically, transcriptome sequencing demonstrates that the PI3K-AKT pathway was significantly inactivated upon Sendeng-4 exposure, which was confirmed by western blot showing decreased phosphorylation of AKT. In addition, decreased BCL-2 expression and increased BAX expression were observed, suggesting programmed cell death via apoptosis. Moreover, LC3-II production as well as autophagosomes formation was observed as demonstrated by western blot and immunofluorescence, indicating elevated autophagy network by Sendeng-4 stimulation. Collectively, we concluded that Sendeng-4 might be used as an anticancer drug for melanoma.

Automatic Polyp Segmentation in Colonoscopy Images Using a Modified Deep Convolutional Encoder-Decoder Architecture

Colorectal cancer has become the third most commonly diagnosed form of cancer, and has the second highest fatality rate of cancers worldwide. Currently, optical colonoscopy is the preferred tool of choice for the diagnosis of polyps and to avert colorectal cancer. Colon screening is time-consuming and highly operator dependent. In view of this, a computer-aided diagnosis (CAD) method needs to be developed for the automatic segmentation of polyps in colonoscopy images. This paper proposes a modified SegNet Visual Geometry Group-19 (VGG-19), a form of convolutional neural network, as a CAD method for polyp segmentation. The modifications include skip connections, 5 × 5 convolutional filters, and the concatenation of four dilated convolutions applied in parallel form. The CVC-ClinicDB, CVC-ColonDB, and ETIS-LaribPolypDB databases were used to evaluate the model, and it was found that our proposed polyp segmentation model achieved an accuracy, sensitivity, specificity, precision, mean intersection over union, and dice coefficient of 96.06%, 94.55%, 97.56%, 97.48%, 92.3%, and 95.99%, respectively. These results indicate that our model performs as well as or better than previous schemes in the literature. We believe that this study will offer benefits in terms of the future development of CAD tools for polyp segmentation for colorectal cancer diagnosis and management. In the future, we intend to embed our proposed network into a medical capsule robot for practical usage and try it in a hospital setting with clinicians.